Laparoscopic Pectopexy With and Without Mesh Use for Pelvic Organ Prolapse.
Comparison of Pectopexy Operations With and Without Mesh Use After Laparoscopic Hysterectomy for Pelvic Organ Prolapse.
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Detailed Description
Study Type
Study Type
Enrollment (Estimated)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Contact
Study Contact
- Name: Şener Gezer, M.D.
- Phone Number: +903723037575
- Email: dr.senergezer@gmail.com
Study Locations
-
-
Kocaeli
-
Köseköy, Kocaeli, Turkey (Türkiye), 41380
- Recruiting
- Kocaeli University, School of Medicine
-
Contact:
- Şener Gezer, Asoc. Prof. Dr.
- Phone Number: +90 372 303 2525
- Email: dr.senergezer@gmail.com
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Female patients older than 40 years and younger than 80 years old with symptomatic uterine prolapse
- Patients who provided written consent for the surgical procedure
- Patients who do not wish to preserve their uterus
Exclusion Criteria:
- Patients who cannot obtain anesthesia approval for laparoscopic surgery
- Patients who have a confirmed or suspected pregnancy
- Patients who have abnormal uterine/cervical/vaginal bleeding
- Patients with biopsy-confirmed endometrial hyperplasia or cervical dysplasia
- Patients with pathology-confirmed genital cancer
- Patients undergone chemotherapy or radiotherapy for any type of cancer
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Laparoscopic Pectopexy without mesh
In this group of patients, the Laparoscopic Pectopexy operation will be performed without the use of mesh material after hysterectomy.
Not using mesh will be protective against possible erosion reactions that may develop in the postoperative period.
Laparoscopic hysterectomy is performed using the standard procedure with a uterine manipulator; after sealing the uterine arteries, the vagina is cut at the level of the uterine manipulator cuff and sutured.
The vaginal cuff will be fixed to the pectineal ligament with No. 1, non-absorbable Prolene suture.
|
The vaginal cuff will be fixed to the pectineal ligament with No. 1, non-absorbable Prolene suture.
|
|
Active Comparator: Laparoscopic Pectopexy with mesh
In this group of patients, the Laparoscopic Pectopexy operation will be performed using mesh material after hysterectomy.
Laparoscopic hysterectomy is performed using the standard procedure with a uterine manipulator; after sealing the uterine arteries, the vagina is cut at the level of the uterine manipulator cuff and sutured.
The vaginal cuff will be fixed to the pectineal ligament with polypropylene mesh.
|
The vaginal cuff will be fixed to the pectineal ligament with polypropylene mesh.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Apical descensus relapse rate
Time Frame: 12 months after surgery
|
The ratio of women with stage 2 or greater vaginal cuff prolapse according to the Pelvic Organ Prolapse Quantification (POP-Q) system.
|
12 months after surgery
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Prolapse Quality of Life (P-QOL)
Time Frame: Preoperative day and 12 months after surgery
|
The questionnaire has nine items, each of which has a 4-point scoring system and a total score of 0-100.
A high total score indicates worsening of the quality of life of women with pelvic organ prolapse.
|
Preoperative day and 12 months after surgery
|
Other Outcome Measures
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
De novo central or lateral defect cystocele rate
Time Frame: 12 months after surgery
|
The ratio of women with stage 2 or greater central or lateral defect cystocele according to the Pelvic Organ Prolapse Quantification (POP-Q) system
|
12 months after surgery
|
|
De novo rectocele rate
Time Frame: 12 months after surgery
|
The ratio of women with stage 2 or greater rectocele according to the Pelvic Organ Prolapse Quantification (POP-Q) system
|
12 months after surgery
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Study Chair: İsmail Bıyık, M.D., Kütahya Sağlık Bilimleri University
Publications and helpful links
General Publications
- Erdem B, Salman S, Usta ZK, Bacak HB, Ozkan MD, Ceken AT, Isik EY, Kumbasar S, Gencer FK, Baghaki HS, Kacar T, Aslan GN, Bulut B. A Novel Approach for Apical Prolapse Surgery: Meshless Pectopexy (Salman's Modification). Int Urogynecol J. 2025 Aug;36(8):1701-1705. doi: 10.1007/s00192-025-06107-z. Epub 2025 Apr 1.
- Aleksandrov A, Smith AV, Rabischong B, Botchorishvili R. Mesh-less laparoscopic treatment of apical prolapse. Facts Views Vis Obgyn. 2021 Jun;13(2):179-181. doi: 10.52054/FVVO.13.2.013.
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Estimated)
Primary Completion
Study Completion (Estimated)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Hypothalamic Hormones
- Peptide Hormones
- Neuropeptides
- Peptides
- Amino Acids, Peptides, and Proteins
- Nerve Tissue Proteins
- Proteins
- Pituitary Hormones
- Pituitary Hormones, Anterior
- Melanocortins
- Pro-Opiomelanocortin
- Melanocyte-Stimulating Hormones
Other Study ID Numbers
Other Study ID Numbers
- KAEK/18.bI.02
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Genital Prolapse
-
NCT07194343CompletedProlapse; Female | Prolapse Genital | Prolapse Uterovaginal
-
NCT06404931RecruitingProlapse; Female | Prolapse Genital | Prolapse Uterovaginal
-
NCT03534830Completed
-
NCT00784602TerminatedGenital Prolapse
-
NCT02585544CompletedGenital Prolapse | Vaginal Floor Prolapse
-
NCT03077490Completed
-
NCT07245823Recruiting
-
NCT05691543Not yet recruiting
-
NCT03200327Terminated
Clinical Trials on Meshless Laparoscopic Pectopexy
-
NCT05876975Recruiting
-
NCT05558852RecruitingLaparoscopy | Prolapse Uterovaginal | Prolapse Bladder
-
NCT07596498Recruiting
-
NCT07411898Active, not recruitingPelvic Organ Prolapse | Pelvic Organ Prolapse Vaginal Surgery | Sacrocolpopexy | Pectopexy
-
NCT07080957Completed
-
NCT06072456Completed
-
NCT06524700Active, not recruitingUterine Prolapse | Vault Prolapse, Vaginal
-
NCT04508062Completed